Podcast: Citeline Japan Awards 2024 - Enter Now!

15 July Deadline

The 15 July entry deadline for the Citeline Japan Awards 2024 in Tokyo is fast approaching, so here's a reminder to take a look at the categories and criteria and be sure you get those submissions in by this date. Sponsorship opportunities and tables are also available. 

cliteline japan awards banner
15 July deadline for Citeline Japan Awards Entries • Source: Citeline

(Japanese follows English.) The Citeline Japan Awards 2024 will take place at the Palace Hotel in Tokyo on 22 October. This will be the third year for our growing Awards event in Japan, which has met with great success and much interest from the industry in this key global pharma market.

The entry deadline of 15 July is fast approaching so if you are thinking about making an entry, please take a look at the categories and criteria and submit your entry forms for the seven enterable categories by this date.

These include Best New Drug, Executive of the Year, Biotech Company of the Year, Best Contract Research Organization, Best Contract Development Manufacturing Organization, Licensing Deal of the Year, and Financing Deal of the Year.

Nominations can also be made for Pharma Company of the Year and the Lifetime Achievement Award, for which the winners are decided by a senior Citeline team.

The benefits of making an entry include exposure for your company through possible shortlisting and of course any final winners as decided by our distinguished independent judging panel would benefit from receiving the prestigious award and the recognition that comes from this.

A full guide on the criteria for each category and how to make an entry, along with all other information on the event, are available in English and Japanese at the links below. Also take this chance to book your table for the awards ceremony, which provides a great networking opportunity as well as an enjoyable evening at a wonderful venue in the heart of Tokyo.

Thank you and we look forward to seeing you there in October!

Citeline · Citeline Japan Awards 2024 - Enter Now! (Bilingual English/Japanese)

Open Media

(Japanese)

日本から世界の製薬市場やバイオテック市場で活躍する企業をたたえるイベント、Citeline Japan Awards は、おかげさまで3回目を迎え、今回も2024年10月22日にパレスホテル東京で開催します。

今回の表彰カテゴリーは、

  • 最も優れた新薬を表彰するBest New Drug
  • 最も活躍した経営者や幹部を表彰するExecutive of the Year 
  • 目覚ましい活躍を見せたバイオテック企業を表彰するBiotech Company of the Year
  • 最も優れたCRO、そしてCDMOをそれぞれたたえるBest CRO、Best CDMO
  • 最も注目された導出、導入の契約案件を選出するLicensing Deal of the Year
  • 優れた協業、買収契約案件を選出するFinancing Deal of the Year

の、7つとなっています。アワードは、運営企業から独立した専門家のチームが厳正な審査を行い、受賞者を決定します。

エントリーの期限は7月15日まで。エントリーを検討されるかたは、ぜひお早めに、概要欄のリンクから、日本語版または英語版のガイドラインをご覧ください。

あわこれら7つのカテゴリーのほか、最も活躍した製薬企業をたたえるPharma Company of the Year、長いキャリアを通じて製薬業界に貢献した人物をたたえるLifetime Achievement Awardの受賞者を独自に選出いたします。

本アワードは、日本の製薬・バイオテック業界という舞台で、たがいに切磋琢磨しながら活躍するさまざまな企業の参加者たちとディナーやカクテルを楽しみながら、今後の人脈を広げていただく場にもなっております。

また、エントリーだけでなく、ぜひ会場のテーブルをご予約いただき、ご来場ください。

English-language Awards site: https://www.citeline.com/en/awards/citelinejapanawards

Japanese-language Awards site: https://www.citeline.com/ja-jp/awards/citelinejapanawards

More from Japan

Japan Looks To Build Domestic Capacity In New Modalities

 
• By 

Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By 

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

Japan Pushes Generic Industry Reforms Via New Govt Fund

 
• By 

Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.

Japan Expands Priority R&D List For Regular Vaccinations

 
• By 

Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.

More from Asia

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By 

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By 

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By 

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.